Telos Capital Management Inc. Buys 1,776 Shares of Zoetis Inc. (NYSE:ZTS)

Telos Capital Management Inc. raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.3% in the fourth quarter, Holdings Channel reports. The fund owned 42,706 shares of the company’s stock after acquiring an additional 1,776 shares during the period. Telos Capital Management Inc.’s holdings in Zoetis were worth $6,958,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the third quarter valued at about $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the third quarter valued at about $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Fortitude Family Office LLC raised its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZTS has been the subject of a number of research analyst reports. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Price Performance

Zoetis stock opened at $174.07 on Friday. The firm has a market capitalization of $78.54 billion, a P/E ratio of 32.72, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The business has a 50-day moving average of $169.39 and a 200-day moving average of $179.32. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.36 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Tuesday, January 21st. Zoetis’s payout ratio is presently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.